This is a working overview of Cyclic heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
| Property | Value | Notes |
|---|---|---|
| Primary receptor targets | MC4R and MC1R | Agonist activity; MC3R and MC5R weaker |
| Route studied in trials | Subcutaneous injection | Intranasal form was not approved |
| Elimination half-life | Approximately 2–3 hours | Short relative to the dosing interval |
| Common analytical method | Liquid chromatography–tandem mass spectrometry | Used for peptide quantification in plasma |
| Reported adverse events | Nausea, flushing, headache | Transient blood pressure rise also noted |
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
== Use and effects == EiPLA has been identified in blotter containing doses of 86 to 97 μg base equivalent per tab. Blotter containing 200 μg per tab has also been described. Anecdotal reports suggest that EiPLA produces psychedelic effects but is less potent than LSD.
== Enrichment steps == The peptide-mRNA:cDNA fusions can be selected over immobilized selection targets for several rounds (Figure 3). There might be a relatively high background for the first few rounds of selection, and this can be minimized by increasing selection stringency, such as adjusting salt concentration, amount of detergent, and/or temperature during the target/fusion binding period. Following binding selection, those library members that stay bound to the immobilized target are PCR amplified. The PCR amplification step will enrich the population from the mRNA-display library that has higher affinity for the immobilized target. Error-prone PCR can also be done in between each round of selection to further increase the diversity of the mRNA-display library and reduce background in selection. A less time-consuming protocol for mRNA display was recently published.
== Uses == Several species in the genus bear edible fruit and are commonly cultivated: Breadfruit (Artocarpus altilis), Cempedak (Artocarpus integer), Jackfruit (Artocarpus heterophyllus), Kwai Muk (Artocarpus parvus), Lakoocha (Artocarpus lakoocha), Pudau (Artocarpus kemando), Anjily (a.k.a. Jungle Jack) (Artocarpus hirsutus), Chaplaish (Artocarpus chama), and Marang (Artocarpus odoratissimus). Breadfruit and jackfruit are cultivated widely in the tropical Southeast Asia. Other species are cultivated locally for their timber, fruit or edible seeds. Anjily, A. hirsutus, is grown for fruit and timber in the Western Ghats.
== History == Omadacycline was invented at Tufts University School of Medicine by a research team led by Mark L. Nelson with Mohamed Ismail while at Tufts and Kwasi Ohemeng and Laura Honeyman at Paratek Pharmaceuticals, Boston. The team applying their chemistry methods to the tetracycline scaffolds created over 3000 new derivatives, leading to the novel third-generation compounds omadacycline and sarecycline.
== Regulation == The enzymes that catalyse glycolysis are regulated via a range of biological mechanisms in order to control overall flux through the pathway. This is vital for both homeostasis in a static environment, and metabolic adaptation to a changing environment or need. The details of regulation for some enzymes are highly conserved between species, whereas others vary widely.
Sources: en.wikipedia.org
Arsenic is a grey, metallic looking solid. It has a density of 5.727 g/cm3 and is brittle, and moderately hard (more than aluminium; less than iron). It is stable in dry air but develops a golden bronze patina in moist air, which blackens on further exposure. Arsenic is attacked by nitric acid and concentrated sulfuric acid. It reacts with fused caustic soda to give the arsenate Na3AsO3 and hydrogen gas. Arsenic sublimes at 615 °C. The vapour is lemon-yellow and smells like garlic. Arsenic only melts under a pressure of 38.6 atm, at 817 °C. It is a semimetal with an electrical conductivity of around 3.9 × 104 S•cm−1 and a band overlap of 0.5 eV. Liquid arsenic is a semiconductor with a band gap of 0.15 eV. The chemistry of arsenic is predominately nonmetallic. Whether or not arsenic forms a cation is unclear. Its many metal alloys are mostly brittle. It shows fewer tendencies to anionic behaviour than ordinary nonmetals. Its solution chemistry is characterised by the formation of oxyanions. Arsenic generally forms compounds in which it has an oxidation state of +3 or +5. The halides, and the oxides and their derivatives are illustrative examples. In the trivalent state, arsenic shows some incipient metallic properties. The halides are hydrolysed by water but these reactions, particularly those of the chloride, are reversible with the addition of a hydrohalic acid. The oxide is acidic but, as noted below, (weakly) amphoteric. The higher, less stable, pentavalent state has strongly acidic (nonmetallic) properties.
Cory Dell'Olio (born 8 December 1989) is an Australian rules football player who last played for the Essendon Football Club in the Australian Football League, before he was delisted at the end of the 2014 season. He was recruited with pick #29 in the 2011 Rookie Draft, having played as a small forward for the South Fremantle Football Club in the WAFL. Prior to round 4 of the 2012 AFL season he was elevated to the senior list to replace Brent Prismall who was on the long-term injury list with an ACL injury. He made his debut that weekend against Carlton, starting the game as the substitute player and replacing Michael Hurley in the third quarter. He was delisted by Essendon at the end of the 2014 season after only playing three games in 2013 and five in 2014. He returned to South Fremantle the following year. Dell'Olio, along with 33 other Essendon players, was found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his team-mates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, but a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency. He was suspended for two years which, with backdating, ended in November 2016; as a result, he served approximately fourteen months of his suspension and missed the entire 2016 WAFL season.
== Further reading == Müller, Rainer H.; Mäder, Karsten; Gohla, Sven (3 July 2000). "Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art". European Journal of Pharmaceutics and Biopharmaceutics. 50 (1): 161–177. doi:10.1016/S0939-6411(00)00087-4. PMID 10840199. Shah, Mansi K.; Madan, Parshotam; Lin, Senshang (June 2014). "Preparation, in vitro evaluation and statistical optimization of carvedilol-loaded solid lipid nanoparticles for lymphatic absorption via oral administration". Pharmaceutical Development and Technology. 19 (4): 475–485. doi:10.3109/10837450.2013.795169. PMID 23697916. S2CID 42174732. Shah, Mansi K.; Madan, Parshotam; Lin, Senshang (3 October 2015). "Elucidation of intestinal absorption mechanism of carvedilol-loaded solid lipid nanoparticles using Caco-2 cell line as an in-vitro model". Pharmaceutical Development and Technology. 20 (7): 877–885. doi:10.3109/10837450.2014.938857. PMID 25069593. S2CID 40506806.
In 2018, researchers at Georgia Institute of Technology identified three molecular candidates for the bases that might have formed an earliest version of proto-RNA: barbituric acid, melamine, and 2,4,6-triaminopyrimidine (TAP). These three molecules are simpler versions of the four bases in current RNA, which could have been present in larger amounts and could still be forward-compatible with them but may have been discarded by evolution in exchange for more optimal base pairs. Specifically, TAP can form nucleotides with a large range of sugars. Both TAP and melamine base pair with barbituric acid. All three spontaneously form nucleotides with ribose. A 2024 study synthesized a 45-nucleotide polymerase ribozyme named QT45, discovered from random sequence pools, that catalyzes general RNA-templated RNA synthesis. It can synthesize both its complementary strand and a copy of itself with fair accuracy. The authors speculate that polymerase ribozymes are more abundant in RNA sequence space than previously thought.
As both the amine and carboxylic acid groups of amino acids can react to form amide bonds, one amino acid molecule can react with another and become joined through an amide linkage. This polymerization of amino acids is what creates proteins. This condensation reaction yields the newly formed peptide bond and a molecule of water. In cells, this reaction does not occur directly; instead, the amino acid is first activated by attachment to a transfer RNA molecule through an ester bond. This aminoacyl-tRNA is produced in an ATP-dependent reaction carried out by an aminoacyl tRNA synthetase. This aminoacyl-tRNA is then a substrate for the ribosome, which catalyzes the attack of the amino group of the elongating protein chain on the ester bond. As a result of this mechanism, all proteins made by ribosomes are synthesized starting at their N-terminus and moving toward their C-terminus. However, not all peptide bonds are formed in this way. In a few cases, peptides are synthesized by specific enzymes. For example, the tripeptide glutathione is an essential part of the defenses of cells against oxidative stress. This peptide is synthesized in two steps from free amino acids. In the first step, gamma-glutamylcysteine synthetase condenses cysteine and glutamate through a peptide bond formed between the side chain carboxyl of the glutamate (the gamma carbon of this side chain) and the amino group of the cysteine. This dipeptide is then condensed with glycine by glutathione synthetase to form glutathione. In chemistry, peptides are synthesized by a variety of reactions.
Sources: en.wikipedia.org
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.
Nausea, flushing, headache, and transient blood pressure elevation are the most frequently reported events. These typically appear shortly after dosing and are usually described as mild to moderate in severity. Safety data covering long periods of continuous use remain limited.
A short half-life means the compound clears from circulation within hours, so any effect is tied closely to dosing time. Accumulation between doses is therefore unlikely under the studied schedule. The practical consequence is that timing of administration shapes what observers record.
Bremelanotide binds several melanocortin receptors, and MC4R is the subtype most often cited as responsible for its behavioural effects. Activity at MC1R, MC3R and MC5R is also reported. Selectivity is therefore described as limited rather than precise.